Paratek Pharmaceuticals Inc. (NASDAQ:PRTK)’s share price rose 0.4% during trading on Tuesday . The company traded as high as $13.88 and last traded at $13.73, with a volume of 104,193 shares. The stock had previously closed at $13.67.

PRTK has been the topic of a number of recent research reports. Cantor Fitzgerald restated a “buy” rating on shares of Paratek Pharmaceuticals in a research note on Wednesday, May 4th. Ladenburg Thalmann raised their price objective on Paratek Pharmaceuticals from $46.00 to $52.00 and gave the stock a “buy” rating in a research note on Friday, June 17th. HC Wainwright raised their price objective on Paratek Pharmaceuticals from $31.00 to $34.00 and gave the stock a “buy” rating in a research note on Friday, June 17th. Leerink Swann restated a “buy” rating and set a $35.00 price objective on shares of Paratek Pharmaceuticals in a research note on Sunday, May 15th. Finally, Zacks Investment Research upgraded Paratek Pharmaceuticals from a “hold” rating to a “buy” rating and set a $18.00 price objective on the stock in a research note on Wednesday, March 23rd. One equities research analyst has rated the stock with a sell rating and eight have issued a buy rating to the company’s stock. Paratek Pharmaceuticals has an average rating of “Buy” and a consensus target price of $35.67.

The firm’s 50 day moving average is $15.01 and its 200-day moving average is $15.16. The stock’s market cap is $235.41 million.

Paratek Pharmaceuticals (NASDAQ:PRTK) last posted its quarterly earnings data on Monday, May 2nd. The specialty pharmaceutical company reported ($1.77) EPS for the quarter, missing the consensus estimate of ($1.25) by $0.52.

In other news, major shareholder Fund Iv L.P. Omega acquired 461,538 shares of the company’s stock in a transaction that occurred on Monday, June 27th. The shares were acquired at an average price of $13.00 per share, for a total transaction of $5,999,994.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Michael Bigham acquired 20,000 shares of the company’s stock in a transaction that occurred on Thursday, June 23rd. The stock was purchased at an average price of $13.45 per share, for a total transaction of $269,000.00. Following the purchase, the chief executive officer now owns 100,000 shares of the company’s stock, valued at approximately $1,345,000. The disclosure for this purchase can be found here.

An institutional investor recently raised its position in Paratek Pharmaceuticals stock. Turner Investments L.P. raised its position in shares of Paratek Pharmaceuticals Inc. (NASDAQ:PRTK) by 16.5% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 61,430 shares of the specialty pharmaceutical company’s stock after buying an additional 8,710 shares during the period. Turner Investments L.P. owned about 0.35% of Paratek Pharmaceuticals worth $1,165,000 at the end of the most recent quarter.

Paratek Pharmaceuticals, Inc (Paratek), formerly Transcept Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of antibacterial therapeutics based upon tetracycline chemistry. Paratek’s antibacterial product candidates are omadacycline and sarecycline. Omadacycline is a broad-spectrum antibiotic for use as an empiric monotherapy for community-acquired bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP) and urinary tract infections (UTI).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.